MJMarielle Jarjat

Marielle Jarjat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marielle Jarjat has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Alessandra Tempio

    CNRS, UMR7275, Universite Cote d Azur, Institut de Pharmacologie Moleculaire et Cellulaire, 06560 Valbonne, France

    1 shared publication
  • Andrei Turtoi

    Tumor microenvironment and resistance to treatment Laboratory, Institut de Recherche en Cancérologie de Montpellier (IRCM), Université de Montpellier (UM), Institut Régional du Cancer de Montpellier (ICM), Montpellier, France

    1 shared publication
  • Asma Boulksibat

    CNRS, UMR7275, Universite Cote d Azur, Institut de Pharmacologie Moleculaire et Cellulaire, 06560 Valbonne, France

    1 shared publication
  • Barbara Bardoni

    Institut de Pharmacologie Moléculaire et Cellulaire CNRS UMR7275 - Inserm U1323 -Université Côte d’Azur 660 route des Lucioles – Sophia Antipolis 06560 Valbonne

    1 shared publication
  • Carole Rovère

    Institut de Pharmacologie Moléculaire et Cellulaire du CNRS, Université de Nice-Sophia Antipolis, Valbonne, France

    1 shared publication
  • Clara Sanchez

    Université Côte d’Azur, CNRS, IPMC, Valbonne, France

    1 shared publication

Latest Publications

  • Open Access

    Defects in AMPAR trafficking and microglia activation underlie socio-cognitive deficits associated to decreased expression of Phosphodiesterase 2A

    by Sébastien Delhaye, Marielle Jarjat, Asma Boulksibat, Clara Sanchez, Alessandra Tempio, Andrei Turtoi, Mauro Giorgi, Sandra Lacas-Gervais, Gabriele Baj, Carole Rovere, et al.

    Phosphodiesterase 2A (PDE2A) is an enzyme involved in the homeostasis of cAMP and cGMP and is the most highly expressed PDE in human brain regions critical for socio-cognitive behavior. In cortex and hippocampus, PDE2A expression level is upregulated in Fmr1 -KO mice, a model of the Fragile X Syndrome (FXS), the most common form of inherited intellectual disability (ID) and autism spectrum disorder (ASD). Indeed, PDE2A translation is negatively modulated by FMRP, whose functional absence causes FXS. While the pharmacological inhibition of PDE2A has been associated to its pro-cognitive role in normal animals and in models of ID and ASD, homozygous PDE2A mutations have been identified in patients affected by ID, ASD and epilepsy. To clarify this apparent paradox about the role of PDE2A in brain development, we characterized here Pde2a +/− mice (homozygote animals being not viable) at the behavioral, cellular, molecular and electrophysiological levels. Pde2a +/− females display a milder form of the disorder with reduced cognitive performance in adulthood, conversely males show severe socio-cognitive deficits throughout their life. In males, these phenotypes are associated with microglia activation, elevated glutathione levels and increased externalization of GluR1 in CA1, producing reduced mGluR-dependent LTD. Overall, our results reveal molecular targets of the PDE2A-dependent pathway underlying socio-cognitive performance. These results clarify the mechanism of action of pro-cognitive drugs based on PDE2A inactivation, which have been shown to be promising therapeutic approaches for Alzheimer Disease, schizophrenia, FXS as well as other forms of ASD.